Receptor and non-receptor-bearing lymphocytes in untreated systemic lupus erythematosus. Variations with disease activity
Díaz-Jouanen, E.; Rivero, S.J.; Llorente, L.; Alarcón-Segovia, D.
Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 29(4): 265-276
1977
ISSN/ISBN: 0034-8376 PMID: 304591 Document Number: 117738
Document emailed within 1 workday
Related Documents
Cárdenas-Mondragón, G.; Ulloa-Aguirre, A.; Isordia-Salas, I.; Goffin, V.; Leaños-Miranda, A. 2007: Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays Journal of Rheumatology 34(7): 1514-1521Singh, V.; Mahoney, J.A.; Petri, M. 2008: Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus Journal of Rheumatology 35(10): 1989-1993
Dubois, E.L.; Chandor, S.; Friou, G.J.; Bischel, M. 1971: Progressive systemic sclerosis and localized scleroderma morphea with positive lupus erythematosus cell test and unusual systemic manifestations compatible with systemic lupus erythematosus presentation of 14 cases including 1 set of identical twins 1 with scleroderma and the other with systemic lupus erythematosus review of the literature Medicine (Baltimore) 50(3): 199-222
Fyfe, A.; Holme, E.R.; Zoma, A.; Whaley, K. 1987: C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patients with systemic lupus erythematosus Clinical and Experimental Immunology 67(2): 300-308
Danis, V.A.; Millington, M.; Huang, Q.; Hyland, V.; Grennan, D. 1995: Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus Disease Markers 12(2): 135-139
Yoshida, K.; Yukiyama, Y.; Miyamoto, T. 1987: Quantification of the complement receptor function on polymorphonuclear leukocytes: its significance in patients with systemic lupus erythematosus Journal of Rheumatology 14(3): 490-496
Wong, H.K.; Kammer, G.M.; Dennis, G.; Tsokos, G.C. 1999: Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression Journal of Immunology 163(3): 1682-1689
Tanaka, Y.; Saito, K.; Suzuki, H.; Eto, S.; Yamashita, U. 1989: Inhibitory effect of anti-class II antibody on the spontaneous activation of B cells in patients with systemic lupus erythematosus. Analysis with IL-1 production and IL-1 receptor expression Journal of Immunology 143(5): 1584-1590
Greco, C.M.; Rudy, T.E.; Manzi, S. 2004: Effects of disease activity, pain, and distress on activity limitations in patients with systemic lupus erythematosus Journal of Rheumatology 31(2): 260-267
Gillies, S.D.; Wesolowski, J.S.; Lo, K.M. 1991: Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing tumor cells. Tumor-infiltrating lymphocyte/hormone receptor/recombinant antibody Journal of Immunology 146(3): 1067-1071
Sarkar, R.N.; Bhattacharya, K.; Banerjee, M. 2016: Mean platelet volume as an indicator of disease activity in systemic lupus erythematosus Journal of the Association of Physicians of India 64(1): 68-69
Bellamy, A.S.; Calder, V.L.; Feldmann, M.; Davison, A.N. 1985: The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes Clinical and Experimental Immunology 61(2): 248-256
Konca, K.; Erken, E.; Ozbek, S. 1996: Do antineutrophil cytoplasmic antibodies correlate with disease activity in systemic lupus erythematosus? Journal of Rheumatology 23(11): 2007-2008
Leaños-Miranda, A.; Pascoe-Lira, D.; Chávez-Rueda, K.A.; Blanco-Favela, F. 2001: Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity Journal of Rheumatology 28(7): 1546-1553
Pacilio, M.; Migliaresi, S.; Meli, R.; Ambrosone, L.; Bigliardo, B.; Di Carlo, R. 2001: Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity Journal of Rheumatology 28(10): 2216-2221
El-Garf, A.; Salah, S.; Shaarawy, M.; Zaki, S.; Anwer, S. 1996: Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and CNS manifestations Journal of Rheumatology 23(2): 374-377
Blanco-Favela, F.; Quintal-Alvarez, G.; Leaños-Miranda, A. 1999: Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power Journal of Rheumatology 26(1): 55-59
Semenzato, G.; Agostini, C.; Trentin, L.; Zambello, R.; Chilosi, M.; Cipriani, A.; Ossi, E.; Angi, M.R.; Morittu, L.; Pizzolo, G. 1984: Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients Clinical and Experimental Immunology 57(2): 331-337
Carr, R.; Forsyth, S.; Sadi, D. 1987: Abnormal responses to ingested substances in murine systemic lupus erythematosus: apparent effect of a casein-free diet on the development of systemic lupus erythematosus in NZB/W mice Journal of Rheumatology. Suppl 14(Suppl 13): 158-165
Tselios, K.; Sarantopoulos, A.; Gkougkourelas, I.; Boura, P. 2014: CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study Clinical and Experimental Rheumatology 32(5): 630-639